DAPT Maintains Early Neurologic Function in Mild-Moderate Stroke
(MedPage Today) -- In certain patients with mild-to-moderate acute ischemic stroke, dual antiplatelet therapy (DAPT) with aspirin and clopidogrel (Plavix) reduced early neurologic deterioration better than aspirin alone, the Chinese randomized... (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - March 13, 2024 Category: Cardiology Source Type: news
Jan 12 2024 This Week in Cardiology Jan 12 2024 This Week in Cardiology
GLP-1s and BaroStim Neo revisited, a new drug for transthyretin amyloid CM, clopidogrel vs ASA years after PCI and stent, and statins are the topics John Mandrola, MD, discusses in this week ' s podcast.theheart.org on Medscape (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - January 12, 2024 Category: Cardiology Tags: Cardiology Commentary Source Type: news
Long-term Clopidogrel Has Advantages After Coronary Stenting Long-term Clopidogrel Has Advantages After Coronary Stenting
Clopidogrel after PCI was noninferior to aspirin for net adverse clinical events but superior in reducing secondary endpoints of stroke and MI, in 5-year STOPDAPT-2 results.Medscape Medical News (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - January 5, 2024 Category: Cardiology Tags: Cardiology Source Type: news
New Stroke Prevention: Clopidogrel-Aspirin Within 72 Hours New Stroke Prevention: Clopidogrel-Aspirin Within 72 Hours
Groundbreaking data published in the NEJM questioned the commonly accepted 24-hour time window for administering dual antiplatelet therapy following a mild ischemic stroke.Medscape Medical News (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - January 1, 2024 Category: Cardiology Tags: Emergency Medicine Source Type: news
New Stroke Risk Down With Clopidogrel-Aspirin Initiated Within 72 Hours
THURSDAY, Dec. 28, 2023 -- Combined clopidogrel-aspirin therapy initiated within 72 hours after stroke onset leads to lower risk for new stroke at 90 days among patients with mild ischemic stroke or high-risk transient ischemic attack (TIA) of... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - December 28, 2023 Category: Pharmaceuticals Source Type: news
Blood-thinner to treat heart disease proves ineffective for many South Asian patients due to a mutation in their DNA
More than half of those with Bangladeshi and Pakistani ancestry have a genetic mutation that stops the drug clopidogrel from working properly, a study suggests. (Source: the Mail online | Health)
Source: the Mail online | Health - August 26, 2023 Category: Consumer Health News Source Type: news
Common cardiovascular medication ineffective for majority of British South Asians
A new genetic study has found that cardiovascular medication used to prevent heart attacks is much less likely to benefit people of Bangladeshi and Pakistani ancestry than people of European descent. Scientists at Queen Mary University in London discovered that clopidogrel, a commonly prescribed medication used to prevent further heart attacks after an initial event,... Read moreThe post Common cardiovascular medication ineffective for majority of British South Asians appeared first on Nursing in Practice. (Source: Nursing in Practice)
Source: Nursing in Practice - August 24, 2023 Category: Nursing Authors: Carolyn Scott Tags: Cardiology Health inequality Source Type: news
ASA Not Best Antiplatelet in Established CAD: Meta-Analysis ASA Not Best Antiplatelet in Established CAD: Meta-Analysis
Clopidogrel or ticagrelor may be safer and more effective than traditional aspirin for secondary prevention, suggests evidence from seven randomized trials.Medscape Medical News (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - July 14, 2023 Category: Cardiology Tags: Cardiology News Source Type: news
Which Antiplatelet Agent for Patients With TIA and Obesity? Which Antiplatelet Agent for Patients With TIA and Obesity?
Ticagrelor plus aspirin was associated with a lower risk for recurrent stroke than clopidogrel plus aspirin in patients with obesity who carry the CYP2C19 loss-of-function allele.Medscape Medical News (Source: Medscape FamilyMedicine Headlines)
Source: Medscape FamilyMedicine Headlines - July 12, 2023 Category: Primary Care Tags: Cardiology News Source Type: news
Ticagrelor May Reduce Brain Lesions After Carotid Stenting Ticagrelor May Reduce Brain Lesions After Carotid Stenting
The number and volume of emergent ischemic lesions following carotid artery stenting may be reduced with use of ticagrelor vs clopidogrel, secondary findings of the PRECISE-MRI trial suggest.Medscape Medical News (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - June 13, 2023 Category: Cardiology Tags: Neurology & Neurosurgery News Source Type: news
P2Y12 Inhibitor Intensity De-escalation in Patients With ACS P2Y12 Inhibitor Intensity De-escalation in Patients With ACS
A new meta-analysis assesses a DAPT de-escalation strategy based on modulation of DAPT intensity by switching from potent P2Y12 receptor inhibitors to clopidogrel in patients with ACS.European Heart Journal (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - May 17, 2023 Category: Consumer Health News Tags: Cardiology Journal Article Source Type: news
New VOYAGER PAD Analysis Confirms Consistent Benefit of XARELTO ® (rivaroxaban) Plus Aspirin Following Lower Extremity Revascularization (LER)
TITUSVILLE, NJ, March 5, 2023 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced data from a new prespecified analysis from the Phase 3 VOYAGER PAD clinical trial reinforcing the benefits of the XARELTO® (rivaroxaban) vascular dose (2.5 mg twice daily plus aspirin 100 mg once daily) over standard of care (aspirin alone), demonstrating consistent benefit at 30 days, 90 days and up to three years following LER in patients with PAD. Lower extremity revascularization, also called peripheral revascularization, is a procedure that restores blood flow in blocked arteries or veins. This analysis of ...
Source: Johnson and Johnson - March 5, 2023 Category: Pharmaceuticals Tags: Latest News Source Type: news
Pharmacogenomics in Stroke and Cardiovascular Disease Pharmacogenomics in Stroke and Cardiovascular Disease
This review provides an overview of the genetic variants that influence individual responses to aspirin, clopidogrel, warfarin, and statins and the clinical implications for stroke patients.Stroke (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - January 26, 2023 Category: Consumer Health News Tags: Neurology & Neurosurgery Journal Article Source Type: news
Indobufen Noninferior to Aspirin for DAPT After PCI: OPTION Indobufen Noninferior to Aspirin for DAPT After PCI: OPTION
Antiplatelet agent indobufen was noninferior to aspirin in combination with clopidogrel after coronary intervention on both efficacy and safety outcomes, with less mostly minor bleeding.Medscape Medical News (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - November 28, 2022 Category: Cardiology Tags: Cardiology News Source Type: news
Clopidogrel Recall; COAPT Score; Pediatric Cardiologist's Child Porn
(MedPage Today) -- FDA advised that generic lots of atenolol and clopidogrel (Plavix) are under recall due to a label mix-up by manufacturer Golden State Medical Supply.
LivaNova's LifeSPARC advanced circulatory support system has its controller... (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - October 4, 2022 Category: Cardiology Source Type: news
